What is HC Wainwright's Estimate for ARTV Q1 Earnings?

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Equities research analysts at HC Wainwright raised their Q1 2025 EPS estimates for shares of Artiva Biotherapeutics in a research note issued to investors on Wednesday, March 26th. HC Wainwright analyst E. White now expects that the company will post earnings of ($0.68) per share for the quarter, up from their previous estimate of ($0.76). HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics' current full-year earnings is ($4.95) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics' Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.89) EPS, FY2026 earnings at ($3.44) EPS and FY2027 earnings at ($4.10) EPS.

A number of other research firms have also recently issued reports on ARTV. Cantor Fitzgerald lowered their price objective on Artiva Biotherapeutics from $23.00 to $20.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 25th. Needham & Company LLC reiterated a "buy" rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a research note on Tuesday, March 25th. Finally, Wedbush restated an "outperform" rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a research note on Tuesday, March 25th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $20.40.

Remove Ads

Artiva Biotherapeutics Trading Down 5.1 %

ARTV traded down $0.16 on Friday, hitting $3.00. 64,575 shares of the stock traded hands, compared to its average volume of 113,884. The business has a fifty day moving average price of $4.71 and a two-hundred day moving average price of $9.19. Artiva Biotherapeutics has a 52 week low of $2.96 and a 52 week high of $17.31.

Institutional Trading of Artiva Biotherapeutics

Several hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new position in shares of Artiva Biotherapeutics in the 3rd quarter worth approximately $42,000. China Universal Asset Management Co. Ltd. acquired a new position in Artiva Biotherapeutics in the fourth quarter worth $52,000. Wells Fargo & Company MN grew its holdings in shares of Artiva Biotherapeutics by 64.0% during the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company's stock worth $87,000 after purchasing an additional 3,361 shares during the last quarter. MetLife Investment Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at $135,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at $166,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.